Almac, Merck KGaA Partner on Cetuximab Markers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almac Diagnostics will collaborate with Merck KGaA and the Medical Research Council on a study of potential biomarkers of response to the cancer drug cetuximab (Erbitux).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."